Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
Wharton S, Aronne LJ, Stefanski A, Alfaris NF, Ciudin A, Yokote K, Halpern B, Shukla AP, Zhou C, Macpherson L, Allen SE, Ahmad NN, Klise SR; ATTAIN-1 Trial Investigators.
Wharton S, et al. Among authors: shukla ap.
N Engl J Med. 2025 Nov 6;393(18):1796-1806. doi: 10.1056/NEJMoa2511774. Epub 2025 Sep 16.
N Engl J Med. 2025.
PMID: 40960239
Clinical Trial.